What is HC Wainwright’s Estimate for CRDL FY2024 Earnings?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Equities researchers at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research note issued to investors on Wednesday, December 18th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings of ($0.37) per share for the year, up from their previous forecast of ($0.38). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.33) EPS.

Cardiol Therapeutics Price Performance

Cardiol Therapeutics stock opened at $1.28 on Friday. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $1.69 and a 200 day moving average price of $1.96. Cardiol Therapeutics has a 12-month low of $0.79 and a 12-month high of $3.12. The stock has a market cap of $104.58 million, a P/E ratio of -3.28 and a beta of 0.83.

Institutional Trading of Cardiol Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new position in Cardiol Therapeutics in the third quarter valued at approximately $27,000. Townsquare Capital LLC purchased a new stake in Cardiol Therapeutics in the third quarter valued at $27,000. Jane Street Group LLC acquired a new position in shares of Cardiol Therapeutics in the 3rd quarter valued at $29,000. Foundations Investment Advisors LLC purchased a new position in shares of Cardiol Therapeutics during the 2nd quarter worth $97,000. Finally, Lion Street Advisors LLC increased its position in shares of Cardiol Therapeutics by 7.9% during the 3rd quarter. Lion Street Advisors LLC now owns 273,281 shares of the company’s stock worth $544,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 12.49% of the company’s stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.